GREY:IPHAF - Post by User
Comment by
blogon Jun 10, 2009 9:11am
377 Views
Post# 16057833
RE: FDA (fast track, priority review)
RE: FDA (fast track, priority review)As part of the rolling submission I would imagine Lux has already submitted Isotechnikas phase 1 and 2 studies, also the mouse, rat, Canadian phase three psoriasis, and possibly phase 2b renal. The next submission will be Lux’s own phase three + the Canadian\European psoriasis study.
It’s looking good; all we need is big investors to agree, and of course the FDA